A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from day one
- Coverage possible with 2-week gap before premature birth
- Vaccination during third trimester still offers meaningful protection for infants
Persuasive evidence from recent research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a thorough investigation carried out throughout England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s findings have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation provides healthcare professionals and expectant parents with trust in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a notable picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Study design and parameters
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed actual clinical results rather than experimental conditions, providing real-world data of how the vaccine works when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the hazards
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe adequately. Parents frequently observe their babies fighting for breath, their chests heaving as they attempt to draw enough air into their weakened respiratory system. Whilst the majority of babies improve through clinical support, a limited though important group succumb from RSV-related complications each year, making vaccination as prevention a vital health service priority for protecting the youngest and most vulnerable individuals in the population.
- RSV triggers lung inflammation, resulting in severe breathing difficulties in infants
- Nearly 50% of newborns catch the infection in their first few months of life
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- Few infants die from RSV complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have emphasised the value of pregnant women receiving their jab at the best time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.
The communication from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional differences in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts deploying multiple messaging strategies to connect with women during pregnancy
- Geographic variations in vaccine uptake rates throughout England necessitate strategic intervention
- Regional health providers tailoring initiatives to align with local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness provides real advantages for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this preventative solution, the 80% drop in admissions represents thousands of infants shielded from serious illness. Parents no more face the troubling prospect of seeing their babies struggle for breath or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has markedly changed the landscape of neonatal lung health, offering expectant mothers a active means to protect their youngest infants during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection resulted in severe brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab emphasises the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to women in pregnancy in their late pregnancy, transforming what was once an inevitable seasonal threat into a controllable health concern.